Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity

Journal of Immunology

Volumn 194, Issue 12, 2015, Pages 5937-5947

  Zhang, Yi ^a   Chen, Guo ^a   Liu, Zuqiang ^a   Tian, Shenghe ^a   Zhang, Jiying ^a   Carey, Cara D ^a   Murphy, Kenneth M ^b   Storkus, Walter J ^a,c   Falo, Louis D ^a,c   You, Zhaoyang ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CD103 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; MELANOMA VACCINE; TUMOR ANTIGEN; X BOX BINDING PROTEIN 1; ALPHA E INTEGRINS; ALPHA INTEGRIN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; DOPACHROME ISOMERASE; HEAT SHOCK PROTEIN 72; ISOMERASE; LEUKOCYTE ANTIGEN; REGULATORY FACTOR X TRANSCRIPTION FACTORS; REPRESSOR PROTEIN; SNFT PROTEIN, MOUSE; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BATF3+ DENDRITIC CELL; BLOOD CELL; CANCER IMMUNIZATION; CANCER PREVENTION; CD103+ DENDRITIC CELL; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHATIC DRAINAGE; MELANOMA; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; BONE MARROW; DISEASE MODEL; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; MORTALITY; NEOPLASMS; PATHOLOGY; PHENOTYPE; RAT; SECONDARY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, NEOPLASM; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BONE MARROW; CANCER VACCINES; CROSS-PRIMING; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; HSP72 HEAT-SHOCK PROTEINS; HUMANS; INTEGRIN ALPHA CHAINS; INTERFERON-ALPHA; INTRAMOLECULAR OXIDOREDUCTASES; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASMS; PHENOTYPE; RATS; REPRESSOR PROTEINS; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTOR 3; TRANSCRIPTION FACTORS; VACCINES, DNA;

EID: 84931379870     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500089     Document Type: Article

References (44)

1. Rosenberg, S. A. 2014. Decade in review - cancer immunotherapy: entering the mainstream of cancer treatment. Nat. Rev. Clin. Oncol. 11: 630-632.
2. Palucka, K., and J. Banchereau. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39: 38-48.
3. Kurts, C., B. W. S. Robinson, and P. A. Knolle. 2010. Cross-priming in health and disease. Nat. Rev. Immunol. 10: 403-414.
4. Joffre, O. P., E. Segura, A. Savina, and S. Amigorena. 2012. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12: 557-569.
5. Rice, J., C. H. Ottensmeier, and F. K. Stevenson. 2008. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8: 108-120.
6. Kutzler, M. A., and D. B. Weiner. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9: 776-788.
7. Pol, J., N. Bloy, F. Obrist, A. Eggermont, J. Galon, W. Hervé Fridman, I. Cremer, L. Zitvogel, G. Kroemer, and L. Galluzzi. 2014. Trial watch: DNA vaccines for cancer therapy. OncoImmunology 3: e28185.
8. + dendritic cells in cytotoxic T cell immunity. Science 322: 1097-1100.
9. + dendritic cell subset. Immunol. Rev. 234: 18-31.
10. Poulin, L. F., Y. Reyal, H. Uronen-Hansson, B. U. Schraml, D. Sancho, K. M. Murphy, U. K. Håkansson, L. F. Moita, W. W. Agace, D. Bonnet, and C. Reis e Sousa. 2012. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 119: 6052-6062.
11. + nonlymphoid dendritic cells. Immunity 37: 60-73.
12. + dendritic cells. J. Exp. Med. 208: 2005-2016.
13. Diamond, M. S., M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, et al. 2011. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208: 1989-2003.
14. Spadaro, F., C. Lapenta, S. Donati, L. Abalsamo, V. Barnaba, F. Belardelli, S. M. Santini, and M. Ferrantini. 2012. IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119: 1407-1417.
15. Iwakoshi, N. N., M. Pypaert, and L. H. Glimcher. 2007. The transcription factor XBP-1 is essential for the development and survival of dendritic cells. J. Exp. Med. 204: 2267-2275.
16. + dendritic cells. Nat. Immunol. 15: 248-257.
17. Todd, D. J., A.-H. Lee, and L. H. Glimcher. 2008. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat. Rev. Immunol. 8: 663-674.
18. Smith, J. A., M. J. Turner, M. L. DeLay, E. I. Klenk, D. P. Sowders, and R. A. Colbert. 2008. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-β induction via X-box binding protein 1. Eur. J. Immunol. 38: 1194-1203.
19. Martinon, F., X. Chen, A.-H. Lee, and L. H. Glimcher. 2010. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat. Immunol. 11: 411-418.
20. Hu, F., X. Yu, H. Wang, D. Zuo, C. Guo, H. Yi, B. Tirosh, J. R. Subjeck, X. Qiu, and X. Y. Wang. 2011. ER stress and its regulator X-box-binding protein-1 enhance polyIC-induced innate immune response in dendritic cells. Eur. J. Immunol. 41: 1086-1097.
21. Nakaya, H. I., J. Wrammert, E. K. Lee, L. Racioppi, S. Marie-Kunze, W. N. Haining, A. R. Means, S. P. Kasturi, N. Khan, G.-M. Li, et al. 2011. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12: 786-795.
22. V600E cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41: 544-552.
23. Tian, S., Z. Liu, C. Donahue, L. D. Falo, Jr., and Z. You. 2012. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccineinduced prophylactic and therapeutic antitumor immunity. Mol. Ther. 20: 432-442.
24. Zhang, Y., S. Tian, Z. Liu, J. Zhang, M. Zhang, M. W. Bosenberg, R. M. Kedl, T. A. Waldmann, W. J. Storkus, L. D. Falo, Jr., and Z. You. 2014. Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. OncoImmunology 3: e959321.
25. Kim, J. H., J. Chen, N. Majumder, H. Lin, L. D. Falo, Jr., and Z. You. 2005. "Survival gene" Bcl-xl potentiates DNA-raised antitumor immunity. Gene Ther. 12: 1517-1525.
26. Kim, J. H., N. Majumder, H. Lin, J. Chen, L. D. Falo, Jr., and Z. You. 2005. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer. Mol. Ther. 11: 941-949.
27. Wang, L., L. Rollins, Q. Gu, S. Y. Chen, and X. F. Huang. 2009. A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity. Vaccine 28: 561-570.
28. Singh, V., Q. Ji, L. Feigenbaum, R. M. Leighty, and A. A. Hurwitz. 2009. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J. Immunother. 32: 129-139.
29. Malyshev, I. 2013. Immunity, Tumors and Aging: The Role of HSP70. Springer, New York.
30. Jelinek, I., J. N. Leonard, G. E. Price, K. N. Brown, A. Meyer-Manlapat, P. K. Goldsmith, Y. Wang, D. Venzon, S. L. Epstein, and D. M. Segal. 2011. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 186: 2422-2429.
31. + pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J. Exp. Med. 208: 1789-1797.
32. Cebrian, I., G. Visentin, N. Blanchard, M. Jouve, A. Bobard, C. Moita, J. Enninga, L. F. Moita, S. Amigorena, and A. Savina. 2011. Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. Cell 147: 1355-1368.
33. Kim, J. H., N. Majumder, H. Lin, S. Watkins, L. D. Falo, Jr., and Z. You. 2005. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum. Gene Ther. 16: 1255-1266.
34. Heath, W. R., and F. R. Carbone. 2013. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat. Immunol. 14: 978-985.
35. Honda, K., S. Sakaguchi, C. Nakajima, A. Watanabe, H. Yanai, M. Matsumoto, T. Ohteki, T. Kaisho, A. Takaoka, S. Akira, et al. 2003. Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by doublestranded RNA or viral infection. Proc. Natl. Acad. Sci. USA 100: 10872-10877.
36. Montoya, M., G. Schiavoni, F. Mattei, I. Gresser, F. Belardelli, P. Borrow, and D. F. Tough. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99: 3263-3271.
37. + dendritic cells are protected from influenza virus infection. J. Clin. Invest. 122: 4037-4047.
38. Wollenberg, A., M. Wagner, S. Güunther, A. Towarowski, E. Tuma, M. Moderer, S. Rothenfusser, S. Wetzel, S. Endres, and G. Hartmann. 2002. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. 119: 1096-1102.
39. Gregorio, J., S. Meller, C. Conrad, A. Di Nardo, B. Homey, A. Lauerma, N. Arai, R. L. Gallo, J. Digiovanni, and M. Gilliet. 2010. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J. Exp. Med. 207: 2921-2930.
40. Chopin, M., R. S. Allan, and G. T. Belz. 2012. Transcriptional regulation of dendritic cell diversity. Front. Immunol. 3: 26.
41. Hansmann, L., S. Groeger, W. von Wulffen, G. Bein, and H. Hackstein. 2008. Human monocytes represent a competitive source of interferon-α in peripheral blood. Clin. Immunol. 127: 252-264.
42. + T cells in a patient with epithelial cancer. Science 344: 641-645.
43. Corbière, V., J. Chapiro, V. Stroobant, W. Ma, C. Lurquin, B. Lethé, N. van Baren, B. J. Van den Eynde, T. Boon, and P. G. Coulie. 2011. Antigen spreading contributes to MAGE vaccination-induced regression of melano metastases. Cancer Res. 71: 1253-1262.
44. Zhu, Z., V. Singh, S. K. Watkins, V. Bronte, J. L. Shoe, L. Feigenbaum, and A. A. Hurwitz. 2013. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res. 73: 595-604.